Bellicum Pharmaceuticals (BLCM) Trading 5.2% Higher

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) traded up 5.2% on Friday . The company traded as high as $8.70 and last traded at $8.67. 1,639,875 shares traded hands during mid-day trading, an increase of 74% from the average session volume of 940,685 shares. The stock had previously closed at $8.24.

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price objective (down from $12.00) on shares of Bellicum Pharmaceuticals in a research note on Wednesday, January 31st. Citigroup upped their price objective on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, February 16th. Wells Fargo raised shares of Bellicum Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their price objective for the stock from $8.30 to $6.85 in a research note on Wednesday. ValuEngine lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research lowered shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $17.98.

How to Become a New Pot Stock Millionaire

The stock has a market cap of $229.97, a P/E ratio of -3.07 and a beta of 0.47. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.37 and a current ratio of 8.37.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.08. The firm had revenue of ($0.07) million for the quarter, compared to analysts’ expectations of $0.08 million. analysts anticipate that Bellicum Pharmaceuticals, Inc. will post -2.67 EPS for the current fiscal year.

In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total transaction of $2,248,978.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 18.77% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. MYDA Advisors LLC purchased a new position in shares of Bellicum Pharmaceuticals in the 4th quarter valued at approximately $118,000. LPL Financial LLC purchased a new position in shares of Bellicum Pharmaceuticals in the 4th quarter valued at approximately $140,000. Cubist Systematic Strategies LLC purchased a new position in shares of Bellicum Pharmaceuticals in the 3rd quarter valued at approximately $164,000. Ellington Management Group LLC purchased a new position in shares of Bellicum Pharmaceuticals in the 4th quarter valued at approximately $222,000. Finally, Virtus Fund Advisers LLC purchased a new position in shares of Bellicum Pharmaceuticals in the 4th quarter valued at approximately $343,000. 54.57% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Bellicum Pharmaceuticals (BLCM) Trading 5.2% Higher” was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://transcriptdaily.com/2018/04/13/bellicum-pharmaceuticals-blcm-trading-5-2-higher.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply